Instructions for Authors
Comprehensive guidelines for preparing and submitting your oncology manuscript.
Publication Excellence in Cancer Research
The Journal of Neoplasms maintains the highest standards of scientific and clinical publishing. Following these guidelines ensures rapid processing and positions your research for maximum impact within the global oncology community.
Questions? Contact our editorial team at [email protected]
Original Articles
- Full-length research studies
- Maximum 5,000 words body text
- Structured abstract 300 words
- Up to 50 references
- 6 figures/tables combined
- Supplementary data welcome
Review Articles
- Comprehensive topic surveys
- Maximum 7,000 words body text
- Unstructured abstract 250 words
- Up to 100 references
- Summary figures encouraged
- Future directions required
Case Reports
- Exceptional clinical cases
- Maximum 2,500 words body text
- Unstructured abstract 150 words
- Up to 20 references
- Clinical imaging encouraged
- Learning points required
Language and Format
Submit in clear English using Microsoft Word format. Double-space text with consecutive page numbers. Use Times New Roman 12pt or Arial 11pt font consistently throughout the manuscript.
Title Page
Include full title, running title max 50 characters, all author names with affiliations, corresponding author details with email, ORCID identifiers, and word count.
Abstract
Structured abstract max 300 words with Background, Methods, Results, and Conclusions for original research. Include cancer type and key clinical implications studied.
Keywords
Provide 5-7 keywords including cancer type, therapeutic modality, biomarkers, and relevant MeSH terms for optimal oncology database indexing.
Original Research: Introduction, Materials and Methods, Results, Discussion, Conclusions, References
Clinical Trials: Follow CONSORT guidelines with registered trial number. Include CONSORT flow diagram and checklist.
Case Reports: Abstract, Introduction, Case Presentation, Discussion, Learning Points, References
- Describe patient populations with detailed eligibility criteria and consent procedures
- Provide institutional review board/ethics committee approval details with reference numbers
- Specify tumor staging systems (TNM, FIGO) and grading criteria used
- Detail treatment protocols including drug doses, schedules, and supportive care
- Define response criteria (RECIST, iRECIST for immunotherapy) and statistical methods
- Include sample size calculations and power analysis for clinical studies
Survival Analysis
Use Kaplan-Meier curves with log-rank tests. Report median follow-up, censoring patterns, and hazard ratios with 95% confidence intervals.
Clinical Trial Statistics
Pre-specify primary and secondary endpoints. Apply Intent-to-Treat and per-protocol analyses. Report exact P-values and effect sizes.
Multivariate Analysis
Use Cox regression for time-to-event outcomes. Report adjusted hazard ratios with confidence intervals for all covariates.
Biomarker Studies
Report sensitivity, specificity, positive/negative predictive values, and area under ROC curves for diagnostic biomarkers.
Human Subjects
- IRB/Ethics Committee approval mandatory
- Declaration of Helsinki compliance
- Written informed consent documented
- Clinical trial registration required
- Patient privacy protection (HIPAA)
Animal Studies
- IACUC approval mandatory
- ARRIVE 2.0 guidelines compliance
- Tumor model details specified
- Humane endpoints defined
- Anesthesia protocols detailed
Conflicts
- Pharmaceutical relationships declared
- Advisory board participation
- Speaker honoraria disclosed
- Research funding sources
- Patent interests reported
- Resolution: Minimum 300 dpi for images. Use TIFF or high-quality PNG format.
- Kaplan-Meier Curves: Include number at risk tables, censoring marks, and P-values.
- Pathology Images: Include scale bars, staining methods, and magnification.
- Treatment Schemas: Use standardized CONSORT-compatible flow diagrams.
- Tables: Submit as editable text with clear headers and statistical annotations.
- Patient Images: Ensure de-identification. Obtain written consent for any identifiable content.
JN encourages sharing of individual patient data and genomic datasets. Deposit sequence data in GEO or ArrayExpress. Clinical trial data should be available upon reasonable request. Include a Data Availability Statement describing access procedures.
Use Vancouver citation style. Number references consecutively in order of first citation. Include DOIs for all published works. Verify accuracy of all citations, especially clinical trial publications and guidelines.
Randomized controlled trials must follow CONSORT guidelines with completed checklist. Register trials prospectively on ClinicalTrials.gov, EU-CTR, or WHO ICTRP before enrollment. Include trial registration number in abstract. Provide CONSORT flow diagram showing patient disposition through all study phases including screening, randomization, treatment, and follow-up.
Systematic reviews and meta-analyses should follow PRISMA 2020 guidelines with completed checklist. Register protocols on PROSPERO before data extraction begins. Submit search strategies for all databases as supplementary files. Clearly describe risk of bias assessment methods and results.
All manuscripts must include a Data Availability Statement describing how underlying data can be accessed. For clinical data, describe any restrictions due to patient privacy and provide contact information for reasonable data access requests.
Begin Your Submission
Choose your preferred pathway and share your cancer research with the world.
We look forward to receiving your manuscript submission. Together, we advance cancer science and improve patient outcomes globally.
